Buprenorphine 5 mcg/hour Transdermal Patch (Butrans)

What It Is

Indications

• Chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment where alternative options are inadequate
• Considered at WHO Pain Ladder Step 2/3 (between weak opioids like codeine/tramadol and high-dose fentanyl patches)
• Cancer pain (moderate to severe)
• Perioperative analgesia (off-label use in some settings)
• NOT indicated for acute or intermittent pain

Who Gets the 5 mcg/hr Patch Specifically?

Dosing & Titration

• Apply to clean, dry, hairless, intact skin on upper outer arm, upper chest, upper back, or side of chest
• Do not use soaps, alcohol, oils, or lotions on the application site - clean with water only
• Do not cut the patch
• Rotate application sites - allow at least 21 days before reapplying to the same site
• Steady-state is reached within 72 hours - dose adjustments can be made every 3 days
• Titrate in increments of 5 mcg/hr, 7.5 mcg/hr, or 10 mcg/hr
• Up to two patches can be used simultaneously (e.g., two 5 mcg/hr patches = 10 mcg/hr total)
• Maximum dose: 20 mcg/hr total - do not exceed due to QTc prolongation risk

Available Strengths (USA)

Pharmacokinetics

Key Safety Points

• QTc prolongation: At 40 mcg/hr (two 20 mcg/hr patches), QTc prolonged by up to 9.2 msec - this is why maximum dose is capped at 20 mcg/hr in the USA
• Precipitation of withdrawal: In opioid-dependent patients already on full agonists, buprenorphine can precipitate withdrawal - taper prior opioids before conversion
• Fever/heat: Elevated skin temperature can increase absorption (similar caution to fentanyl patches)
• Hepatic impairment: Use with caution
• Renal impairment / elderly: No dose adjustment required - this is an important advantage over other opioids (per Rheumatology textbook, buprenorphine and tapentadol are specifically noted as safer opioid choices for elderly patients)
• Prescribe antiemetics for the first 7-10 days due to high nausea/vomiting incidence at initiation
• Do not use if the pouch seal is broken or patch is cut/damaged

Adverse Effects

• Nausea, vomiting (common at initiation)
• Constipation
• Sedation, dizziness
• Application site reactions
• Headache

Advantages Over Other Opioids

1. Partial agonist - ceiling effect on respiratory depression (safer in overdose than full agonists)
2. No renal dose adjustment needed
3. Once-weekly application improves compliance
4. Lower abuse potential than full agonist patches (Schedule III vs. Schedule II for fentanyl)
5. Evidence of effectiveness in cancer pain and perioperative settings

Buprenorphine Transdermal - Evidence by Pain Condition

1. Chronic Noncancer Pain (General) - STRONGEST EVIDENCE

• Buprenorphine significantly reduced pain vs. placebo (SMD = -0.368, p < 0.001)
• Transdermal route showed the strongest effect size among all formulations: SMD = -0.572, p = 0.001
• Buccal route also effective (SMD = -0.453)
• Not significantly different from active analgesic comparators (non-inferior)
• Effect sustained both short-term (<12 weeks) and long-term (≥12 weeks)
• Quality of evidence: low to moderate (heterogeneity I² = 89%)

2. Chronic Low Back Pain - MIXED / RECENT CONTROVERSY

• No statistically significant reduction in pain intensity vs. placebo (MD = -0.32; 95% CI: -1.04 to 0.40; p = 0.38)
• High heterogeneity (I² = 77.4%)
• Significant improvement in sleep quality (SMD = -0.24, p < 0.001) - a clinically meaningful secondary benefit
• Adverse events were numerically more frequent in the buprenorphine group (RR = 1.98) though not reaching significance
• Conclusion: Current evidence does not support routine use of transdermal buprenorphine for chronic low back pain

Discordance note: The 2023 Wong meta-analysis found significant benefit for low back pain (SMD = -0.383), whereas this 2026 dedicated CLBP meta-analysis did not. The 2026 paper was more focused (only vs. placebo, stricter inclusion criteria) and is the more current and specific evidence.

• Of 15 RCTs of transdermal buprenorphine, 10 out of 15 (67%) showed significant pain reduction vs. comparator
• No serious adverse events reported across any study
• Concluded transdermal buprenorphine is an effective analgesic for chronic pain overall

3. Cancer Pain

• 19 studies, 1421 patients, 16 different intervention comparisons
• Transdermal buprenorphine: 2 studies found it superior to placebo; 1 study found no difference
• No clear dose-response relationship demonstrated
• No head-to-head superiority vs. other strong opioids established
• Quality of evidence rated as very low to moderate due to methodological limitations
• Buprenorphine remains a valid option particularly when oral opioids are not tolerated

4. Diabetic Peripheral Neuropathic Pain - POSITIVE RCT

• 186 patients with DPNP on maximal conventional therapy; started at 5 mcg/hr, titrated up to 40 mcg/hr
• Per-protocol: 86.3% on buprenorphine vs. 56.6% on placebo achieved ≥30% pain reduction at week 12 (p < 0.001) - a clinically meaningful result
• Intention-to-treat: non-significant trend (51.7% vs. 41.3%, p = 0.175) - blunted by high dropout
• High dropout in buprenorphine arm (37/93) mainly from nausea/vomiting - proactive antiemetic use is essential
• Conclusion: effective when tolerated; nausea management is key to success

5. Osteoarthritis in the Elderly - POSITIVE RCT

• 60 patients aged >64 years, severe pain (NRS > 5), randomized to starting doses of 8.75, 17.5, or 35 mcg/hr for 10 days
• Effective analgesia and improved quality of life in all three dose groups
• Improvement seen in pain, mood, sleep, walking ability, and social function
• Lower starting doses (8.75-17.5 mcg/hr) showed better tolerability (less drowsiness, confusion, vomiting) vs. 35 mcg/hr
• No dose-dependent difference in DN4 neuropathic component scores

6. Comparative Safety: Buprenorphine vs. Fentanyl vs. Morphine

• Pain reduction: comparable between transdermal buprenorphine and transdermal fentanyl
• vs. fentanyl: significantly less nausea (OR 0.21) and fewer treatment discontinuations (OR 0.17) with buprenorphine
• vs. morphine: buprenorphine showed greater pain intensity reduction (MD -16.20); morphine caused significantly more constipation (OR 7.50) and more discontinuations
• Conclusion: buprenorphine has a favorable safety profile compared to both fentanyl and morphine

Summary Table

Bottom Line